ICU Medical Inc (ICUI)
107.09
+0.80
(+0.75%)
USD |
NASDAQ |
May 10, 16:00
107.09
0.00 (0.00%)
After-Hours: 20:00
ICU Medical Research and Development Expense (Quarterly): 21.84M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 21.84M |
| December 31, 2023 | 22.41M |
| September 30, 2023 | 20.87M |
| June 30, 2023 | 22.30M |
| March 31, 2023 | 19.76M |
| December 31, 2022 | 23.45M |
| September 30, 2022 | 23.10M |
| June 30, 2022 | 22.56M |
| March 31, 2022 | 23.87M |
| December 31, 2021 | 13.17M |
| September 30, 2021 | 12.24M |
| June 30, 2021 | 11.38M |
| March 31, 2021 | 10.71M |
| December 31, 2020 | 11.80M |
| September 30, 2020 | 10.13M |
| June 30, 2020 | 10.28M |
| March 31, 2020 | 10.75M |
| December 31, 2019 | 12.59M |
| September 30, 2019 | 12.00M |
| June 30, 2019 | 11.20M |
| March 31, 2019 | 12.82M |
| December 31, 2018 | 13.52M |
| September 30, 2018 | 13.18M |
| June 30, 2018 | 13.58M |
| March 31, 2018 | 12.59M |
| Date | Value |
|---|---|
| December 31, 2017 | 13.88M |
| September 30, 2017 | 12.77M |
| June 30, 2017 | 12.97M |
| March 31, 2017 | 11.64M |
| December 31, 2016 | 2.654M |
| September 30, 2016 | 3.65M |
| June 30, 2016 | 3.338M |
| March 31, 2016 | 3.313M |
| December 31, 2015 | 4.057M |
| September 30, 2015 | 4.227M |
| June 30, 2015 | 3.122M |
| March 31, 2015 | 4.308M |
| December 31, 2014 | 5.08M |
| September 30, 2014 | 5.055M |
| June 30, 2014 | 4.566M |
| March 31, 2014 | 3.631M |
| December 31, 2013 | 3.458M |
| September 30, 2013 | 3.14M |
| June 30, 2013 | 3.906M |
| March 31, 2013 | 1.903M |
| December 31, 2012 | 2.22M |
| September 30, 2012 | 2.988M |
| June 30, 2012 | 2.729M |
| March 31, 2012 | 2.693M |
| December 31, 2011 | 2.168M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
10.13M
Minimum
Sep 2020
23.87M
Maximum
Mar 2022
16.32M
Average
12.88M
Median
Research and Development Expense (Quarterly) Benchmarks
| Integer Holdings Corp | 15.75M |
| LeMaitre Vascular Inc | 4.092M |
| ResMed Inc | 77.07M |
| UFP Technologies Inc | -- |
| Perspective Therapeutics Inc | 6.08M |